Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 3, 2012, Pages 704-711

  Holroyd, Eric W ^a   Delacroix, Sinny ^a   Larsen, Katarina ^a   Harbuzariu, Adriana ^a   Psaltis, Peter J ^a   Wang, Ling ^b   Pan, Shuchong ^a   White, Thomas A ^a   Witt, Tyra A ^a   Kleppe, Laurel S ^a   Mueske, Cheryl S ^a   Mukhopadhyay, Debabrata ^b   Simari, Robert D ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

angiogenesis; hemostasis; murine models; thrombosis; tissue factor

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HINDLIMB; IN VITRO STUDY; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BINDING SITES; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HEPARIN; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84857658518     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.243733     Document Type: Article

References (31)

1. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP. Tissue factor: a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost. 2001;86:334-345. (Pubitemid 32663964)
2. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost. 2004;30:31-44. (Pubitemid 38457299)
3. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:1456-1462. (Pubitemid 46809438)
4. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190-199.
5. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004; 10:502-509. (Pubitemid 38667909)
6. Bajaj M, Kuppuswamy M, Saito H, Spitzer S, Bajaj S. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA. 1990;87:8869-8873. (Pubitemid 120007610)
7. Broze G Jr, Miletich J. Isolation of tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci USA. 1987;84: 1886-1890. (Pubitemid 17054118)
8. Broze G, Warren L, Novotny W, Higuchi D, Girard J, Miletich J. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988;71:335-343. (Pubitemid 18089519)
9. Harenberg J, Malsch R, Heene D. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul Fibrinolysis. 1995;6: S50-S56.
10. Girard T, Warren L, Novotny W, Likert K, Brown S, Miletich J, GJ Broze J. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 1989;338:518-520. (Pubitemid 19107996)
11. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86:959-972. (Pubitemid 32975818)
12. Hackeng TM, Maurissen LF, Castoldi E, Rosing J. Regulation of TFPI function by protein S. J Thromb Haemost. 2009;7(suppl 1):165-168.
13. Armesilla AL, Lorenzo E, Gomez del Arco P, Martinez-Martinez S, Alfranca A, Redondo JM. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol. 1999;19:2032-2043. (Pubitemid 29098261)
14. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood. 2005;105:2384-2391. (Pubitemid 40387035)
15. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem. 2001;276:12241-12248.
16. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptorbinding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004;103:3374-3380. (Pubitemid 38525667)
17. Pan S, Kleppe LS, Witt TA, Mueske CS, Simari RD. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost. 2004;92:495-502. (Pubitemid 39248006)
18. White TA, Witt TA, Pan S, Mueske CS, Kleppe LS, Holroyd EW, Champion HC, Simari RD. Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 2010;43:35-45.
19. Masson VV, Devy L, Grignet-Debrus C, Bernt S, Bajou K, Blacher S, Roland G, Chang Y, Fong T, Carmeliet P, Foidart JM, Noel A. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol Proced Online. 2002;4:24-31. (Pubitemid 35455116)
20. Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, Shaked Y, Kerbel R, Lavallee T, Semenza GL. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res. 2007;101:1310-1318. (Pubitemid 350294648)
21. Bhattacharya R, Kwon J, Li X, Wang E, Patra S, Bida JP, Bajzer Z, Claesson-Welsh L, Mukhopadhyay D. Distinct role of PLCβ3 in VEGFmediated directional migration and vascular sprouting. J Cell Sci. 2009; 122:1025-1034.
22. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/Hypoxemia- Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:2029-2035. (Pubitemid 29422232)
23. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem. 1995;270:11322-11326.
24. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem. 2001; 276:32714-32719.
25. Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPI, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost. 1999;81:45-49. (Pubitemid 29041648)
26. Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D, Beliveau R. Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost. 2008;99:576-585. (Pubitemid 351549295)
27. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem. 1999;274:28837-28840.
28. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990;345:84-86.
29. Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, Zachary I. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Biochem Biophys Res Commun. 2001;283:469-479. (Pubitemid 32924715)
30. Yamazaki Y, Tokunaga Y, Takani K, Morita T. Identification of the heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165. Biochem. 2005;44: 8858-8864. (Pubitemid 40840451)
31. Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology. 1999;9:705-711. (Pubitemid 29329014)